CNPLaw LLP boosts its portfolio of private equity deals with the completion of three new transactions

CNPLaw LLP boosts its portfolio of private equity deals with the completion of three new transactions

Deals and cases

 

CNPLaw LLP boosts its portfolio of private equity deals with the completion of three new transactions





CNPLaw LLP’s corporate advisory team ended 2019 and started 2020 strong with the completion of three private equity transactions within the food distribution, pharmaceutical and biotechnology industries. Leading the team was CNPLaw LLP’s Partner, Mr Ken Chia, assisted by Ms Hazel Ho (Senior Associate) and Mr Muhammad Parasuram (Associate). Managing Partner, Ms Lisa Theng was also involved in one of the transactions listed below – CNPLaw acted for a Singapore biotechnology company in its series B funding of S$15 million from US and Japanese venture capital firms.

 

The Three Private Equity Deals Completed

 

1. Acted for one of Japan’s leading fresh produce distributors in its investment of over S$30 million in a Singapore company

On 29 November 2019, CNPLaw LLP finalised a transaction for one of Japan’s leading fresh food distributors in its investment of over SG$30 million in equity and exchangeable debt in a Singapore fresh fruit wholesale trader.

This transaction marks a significant milestone for the client’s entry into the Singapore market. Upon the completion of the transaction, the client commended the CNPLaw team for their “quick response”.

 

2. Acted for a Hong Kong listed pharmaceutical company in its investment of S$2 million in a Singapore biotechnology company

On 5 December 2019, CNPLaw LLP assisted a Hong Kong listed pharmaceutical company to close its investment of S$2 million in a Singapore biotechnology company. The investment was made by the client’s investment arm via the purchase of convertible notes.

The investment contributes towards the advancement of diabetes cell therapy research in Singapore which is currently undertaken by the Singapore biotechnology company.

 

3. Acted for a Singapore biotechnology company in its series B funding of S$15 million from US and Japanese venture capital firms

On 2 January 2020, CNPLaw LLP assisted a Singapore biotechnology company involved in cancer research to raise S$15 million from US and Japanese venture capital firms. This financing round represents the client’s series B funding and strategically positions the client for future market entry into the US.

 

Commenting on the above transactions is Mr Ken Chia:

“We are pleased to service such clients and support their business goals with their global counterparts. The successful completion of these transactions showcases the breadth of our experience across difference industries in the private equity / venture capital realm.” – Mr Ken Chia, Partner at CNPLaw LLP






Get To Know The Lawyers Involved




Lisa Theng managing partner at CNPLaw LLP

Managing Partner

As a managing partner, Lisa sees a need to ensure that our clients see us as their business partner and not a just legal service provider. Our aim is to provide innovative legal solutions for our clients across Asia with a high level of service and support that will help our clients better manage and succeed in their own businesses.

          



Ken Chia Legal Partner at CNPLaw LLP image

Partner

Ken heads the Corporate advisory team in the firm and has an international focus in his corporate and M&A work and worked in business development positions with various subsidiaries of the Hang Lung Group in Shanghai and with Informa plc in Singapore.

     



Hazel Ho Senior Legal Associate at CNPLaw LLP

Senior Associate

Hazel main areas of practice include cross-border M&A, joint ventures, private equity and general corporate advisory. Hazel has advised various companies ranging from tech start-ups to blue-chip MNCs. She is recognised as a “Notable Practitioner” by IFLR1000 for 2019 and 2020.

          



Muhammad Parasuram is an Associate at CNPLaw LLP. He has advised clients from various industries, including F&B, healthcare and pharmaceutical industries, on corporate and compliance matters

Associate

Parasuram (Para) is an associate in the Corporate Advisory Practice Group. Para has advised clients from various industries, including F&B, healthcare and pharmaceutical industries, on corporate and compliance matters. Being fluent in Mandarin, he has also advised numerous clients from China and Taiwan.

          







Private Equity   >   Deals   >   Current Page